Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - NEVRO CORP | d893978d8k.htm |
Exhibit 99.1
Nevro Reports Fourth Quarter and Full Year 2014 Financial Results
Menlo Park, Calif., March 18, 2015 - Nevro Corp. (NYSE:NVRO), a medical device company that has developed and commercialized an innovative, evidence-based neuromodulation platform for the treatment of chronic pain, today reported financial results for the three months and full year ended December 31, 2014.
Recent Accomplishments & Highlights:
| • | In November 2014, completed initial public offering, receiving net proceeds of approximately $131 million |
| • | Revenue of $9.7 million in the fourth quarter of 2014, an increase of 57% over the same period of the prior year |
| • | In January 2015, received an approvable letter from the U.S. Food & Drug Administration (FDA) in response to the company’s pre-market approval (PMA) application for the Senza Spinal Cord Stimulator (SCS) System |
“The Nevro team delivered an impressive fourth quarter to round out a productive 2014,” said Michael DeMane, Chairman and CEO of Nevro. “I am very pleased with the continued adoption of HF10 therapy in international markets, bringing relief to more patients suffering from debilitating chronic pain. Moreover, the company has made tangible progress to advance the PMA approval process in the United States with the recent receipt of an approvable letter from the FDA pursuant to its PMA application for the Senza SCS system.”
Fourth Quarter Financial Results
Revenue for the three months ended December 31, 2014 increased 57% to $9.7 million, from $6.2 million during the same period of the prior year. This increase was primarily attributable to continued adoption of the Senza system in the markets where it is available.
Gross profit for the fourth quarter of 2014 was $6.7 million, or 69% gross margin, up from $3.6 million, or 59% gross margin, in the same period of the prior year. The increase in gross profit was primarily due to higher revenue coupled with decreased cost of revenue as a percentage of sales.
Operating expenses for the fourth quarter of 2014 were $13.8 million, an increase of 36% compared to $10.2 million for the same period of the prior year. The increase in operating expenses was driven primarily by increased headcount and related personnel costs, as well as expenses incurred in preparation for becoming and operating as a publicly-traded company.
Loss from operations for the fourth quarter of 2014 was $7.1 million, compared to $6.5 million for the same period of the prior year.
Full Year Financial Results
Revenue for the year ended December 31, 2014 increased 39% to $32.6 million, from $23.5 million during the prior year. This increase was primarily attributable to continued adoption of the Senza system in the markets where it is available.
Gross profit for the year was $21.3 million, or 65% gross margin, up from $14.0 million, or 60% gross margin, from the prior year. The increase in gross profit was primarily due to higher revenue coupled with decreased cost of revenue as a percentage of sales.
Operating expenses for 2014 were $49.6 million, an increase of 27% compared to $39.2 million for the prior year. The increase in operating expenses was driven primarily by increased headcount and related personnel costs, as well as expenses incurred in preparation for becoming and operating as a publicly-traded company, partially offset by decreased clinical trial expenses year over year.
Loss from operations for 2014 was $28.3 million, compared to $25.2 million for the prior year.
Cash, cash equivalents, and short-term investments were $176.8 million as of December 31, 2014.
Guidance for Full Year 2015
The company estimates international revenue for the full year 2015 to be in a range of $36-38 million, which would represent an 11 to 17 percent increase versus 2014.
Webcast and Conference Call Information
Management will host a conference call today beginning at 1:30 p.m. PT / 4:30 p.m. ET. Individuals interested in listening to the conference call may dial (877) 201-0168 for domestic callers, or (647) 788-4901 for international callers (Conference ID: 70460099), or access the webcast on the “Investors” section of the Company’s web site at: www.nevro.com. The webcast will be available on the Company’s web site for two weeks following the completion of the call.
About Nevro
Headquartered in Menlo Park, California, Nevro is a medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza® spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza system is the only SCS system that delivers Nevro’s proprietary HF10™ therapy. In the United States, the Senza system is limited by federal law to investigational use only. Senza, HF10, Nevro and the Nevro logo are trademarks of Nevro.
Forward-Looking Statements
In addition to the historical information, this press release contains forward-looking statements with respect to our business, capital resources, strategic initiatives and growth reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including regarding our beliefs about accelerating adoption of Senza in international markets; the timing, if any, of FDA marketing approval of Senza in the U.S., and our expectations for international revenue for the full year 2015. These forward-looking statements are based upon information that is currently available to us or our current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including our ability to successfully commercialize our products; the timing of FDA marketing approval of Senza in the U.S. and our U.S. commercial launch of Senza, if any; our ability to manufacture our products to meet demand; the level and availability of third party payor reimbursement for our products; our ability to effectively manage our anticipated growth; our ability to protect our intellectual property rights and proprietary technologies; our ability to operate our business without infringing the intellectual property rights and proprietary technology of third parties; competition in our industry; additional capital and credit availability; our ability to attract and retain qualified personnel; and product liability claims. These factors, together with those that are described in greater detail in our Annual Report on Form 10-K that we expect to file on March 18, 2015, as well as any reports that we may file with the SEC in the future, may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. We expressly disclaim any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements. Our results for the full year and quarter ended December 31, 2014 are not necessarily indicative of our operating results for any future periods.
Investor Relations Contact:
Westwicke Partners
Lynn Pieper
(415) 202-5678
Lynn.pieper@westwicke.com
Nevro Corp.
Consolidated Statements of Comprehensive Loss
(in thousands, except share and per share data)
| Three Months Ended | Year Ended | |||||||||||||||
| December 31, | December 31, | |||||||||||||||
| 2014 | 2013 | 2014 | 2013 | |||||||||||||
| (unaudited) | ||||||||||||||||
| Revenue |
$ | 9,715 | $ | 6,196 | $ | 32,573 | $ | 23,500 | ||||||||
| Cost of revenue |
3,020 | 2,552 | 11,278 | 9,473 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Gross profit |
6,695 | 3,644 | 21,295 | 14,027 | ||||||||||||
| Operating expenses: |
||||||||||||||||
| Research and development |
4,743 | 4,638 | 19,824 | 20,345 | ||||||||||||
| Sales, general and administrative |
9,058 | 5,541 | 29,777 | 18,833 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total operating expenses |
13,801 | 10,179 | 49,601 | 39,178 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Loss from operations |
(7,106 | ) | (6,535 | ) | (28,306 | ) | (25,151 | ) | ||||||||
| Other income (expense): |
||||||||||||||||
| Interest income (expense), net |
(109 | ) | 41 | (16 | ) | 153 | ||||||||||
| Other income (expense), net |
(991 | ) | (163 | ) | (1,880 | ) | (654 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Loss before income taxes |
(8,206 | ) | (6,657 | ) | (30,202 | ) | (25,652 | ) | ||||||||
| Provision for income taxes |
104 | 83 | 478 | 362 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net loss |
(8,310 | ) | (6,740 | ) | (30,680 | ) | (26,014 | ) | ||||||||
| Accretion of convertible preferred stock to redemption value |
(16 | ) | (41 | ) | (147 | ) | (153 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net loss attributable to common stockholders |
(8,326 | ) | (6,781 | ) | (30,827 | ) | (26,167 | ) | ||||||||
| Changes in foreign currency translation adjustment |
(110 | ) | — | (147 | ) | — | ||||||||||
| Changes in gains (losses) on short-term investments |
205 | (13 | ) | 196 | 23 | |||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net change in other comprehensive income (loss) |
95 | (13 | ) | 49 | 23 | |||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Comprehensive loss |
$ | (8,231 | ) | $ | (6,794 | ) | $ | (30,778 | ) | $ | (26,144 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net loss per share attributable to common stockholders, basic and diluted |
$ | (0.59 | ) | $ | (7.27 | ) | $ | (6.94 | ) | $ | (29.84 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
| Weighted average shares used to compute net loss per share, basic and diluted |
14,229,775 | 933,008 | 4,440,663 | 876,932 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
Nevro Corp.
Consolidated Balance Sheets
(in thousands, except share and per share data)
| December 31, | December 31, | |||||||
| 2014 | 2013 | |||||||
| Assets |
||||||||
| Current assets |
||||||||
| Cash and cash equivalents |
$ | 25,287 | $ | 12,409 | ||||
| Short-term investments |
151,521 | 44,123 | ||||||
| Accounts receivable, net |
6,610 | 6,605 | ||||||
| Inventories, net |
14,856 | 10,123 | ||||||
| Prepaid expenses and other current assets |
2,851 | 1,514 | ||||||
|
|
|
|
|
|||||
| Total current assets |
201,125 | 74,774 | ||||||
| Property and equipment, net |
647 | 117 | ||||||
| Other assets |
424 | 220 | ||||||
| Restricted cash |
300 | 300 | ||||||
|
|
|
|
|
|||||
| Total assets |
$ | 202,496 | $ | 75,411 | ||||
|
|
|
|
|
|||||
| Liabilities, Convertible Preferred Stock and Stockholders’ Deficit |
||||||||
| Current liabilities |
||||||||
| Accounts payable |
$ | 4,460 | $ | 3,177 | ||||
| Accrued liabilities and other |
6,338 | 4,727 | ||||||
|
|
|
|
|
|||||
| Total current liabilities |
10,798 | 7,904 | ||||||
| Notes payable |
19,511 | — | ||||||
| Other long-term liabilities |
117 | 62 | ||||||
|
|
|
|
|
|||||
| Total liabilities |
30,426 | 7,966 | ||||||
| Convertible preferred stock |
— | 153,235 | ||||||
| Stockholders’ equity (deficit) |
||||||||
| Common stock, $0.001 par value – 290,000,000 and 472,000,000 shares authorized, 24,865,491 and 1,120,416 shares issued and outstanding at December 31, 2014 and 2013, respectively |
25 | 1 | ||||||
| Additional paid-in capital |
293,945 | 5,331 | ||||||
| Accumulated other comprehensive income |
77 | 28 | ||||||
| Accumulated deficit |
(121,977 | ) | (91,150 | ) | ||||
|
|
|
|
|
|||||
| Total stockholders’ equity (deficit) |
172,070 | (85,790 | ) | |||||
|
|
|
|
|
|||||
| Total liabilities, convertible preferred stock and stockholders’ equity (deficit) |
$ | 202,496 | $ | 75,411 | ||||
|
|
|
|
|
|||||